Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

March 5, 2021March 5, 2021

ALS Mouse Study Finds Favor in Muse Stem Cells

News

Injecting a specific type of stem cells into the bloodstream was able to reduce muscle shrinkage and promote motor neuron survival in a mouse model of amyotrophic lateral sclerosis (ALS), ... Read more

February 25, 2021February 25, 2021

I AM ALS ‘Playbook’ Aims to Foster Patient Advocacy Groups

News

I AM ALS, a nonprofit working for people affected by amyotrophic lateral sclerosis (ALS), is offering a guide to help others who want to follow in its footsteps — creating a ... Read more

February 24, 2021February 24, 2021

FDA, in Initial Review of NurOwn for ALS, Finds Data Lacking

News

Existing safety and effectiveness data from a Phase 3 clinical trial of NurOwn — an investigational cell-based therapy for amyotrophic lateral sclerosis (ALS) — are not sufficient to support the therapy’s approval, ... Read more

February 19, 2021February 19, 2021

Moderate Physical Activity May Slow Muscle Deterioration

News

Moderate physical activity may slow muscle deterioration associated with the progression of amyotrophic lateral sclerosis (ALS), improving patients’ ability to perform daily life activities, a review study has found. This ... Read more

January 15, 2021January 15, 2021

Mexiletine May Lessen Motor Neuron ‘Excitability’ to Ease Cramps, Small Trial Suggests

News

Mexiletine, a heart medication used off-label to treat muscle cramps due to amyotrophic lateral sclerosis (ALS), was found to be well-tolerated and to stabilize the “hyperexcitability” of motor neurons in ... Read more

January 8, 2021January 8, 2021

CNM-Au8 May Be Source of Motor Neuron Gains Being Seen in Phase 2 Trial

News

Nearly half of all patients in a Phase 2 trial of CNM-Au8, Clene Nanomedicine’s lead candidate for the treatment of amyotrophic lateral sclerosis (ALS), showed improvements in the health and ... Read more

January 5, 2021January 5, 2021

Extension Study Will Continue Evaluating Oral Edaravone

News

Mitsubishi Tanabe Pharma America (MTPA) has launched an extension study to assess the long-term effects of an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis ... Read more

December 22, 2020December 22, 2020

4th Potential ALS Therapy, SLS-005, Added to HEALEY Platform Trial

News

A Phase 2b/3 trial investigating the potential of SLS-005 (trehalose) to slow the progression of amyotrophic lateral sclerosis (ALS) has been added to the HEALEY ALS Platform Trial, the first such ... Read more

December 17, 2020December 17, 2020

AstroRx Given at Higher Dose Still Safely Slowing ALS Progression, Trial Reports

News

A single infusion of AstroRx, an off-the-shelf, investigational cell therapy for amyotrophic lateral sclerosis (ALS), safely and significantly slows disease progression in the first three months following treatment, according to ... Read more

July 24, 2020August 13, 2020

Gene Silencing Method Shows Promise to Treat Familial ALS Associated With SOD1 Mutations

News

A single dose of an artificial microRNA — a tiny RNA molecule that is able to control the activity of certain genes — can lower the activity of SOD1, a gene ... Read more

Pin It on Pinterest